🧬Biologics / Biosimilars
Large molecule drugs produced from living cells — antibodies, proteins, and biosimilars that target diseases with high precision.
Market Cap$4.2T
1D-1.08%
Companies1,426
Public Cos83
SECTOR MARKET CAP
$4.2T+13254.0%ALL
TOP COMPANIES
| # | Company | Country | Valuation | Ticker |
|---|---|---|---|---|
| 1 |  | United States | $809.7B | LLY |
| 2 |  | United States | $566.9B | JNJ |
| 3 |  | United States | $362.6B | ABBV |
| 4 |  | United Kingdom | $284.6B | AZN |
| 5 |  | United States | $282.3B | MRK |
| 6 |  | Switzerland | $278.6B | NVS |
| 7 |  | United States | $187.5B | AMGN |
| 8 |  | United States | $153.4B | PFE |
| 9 |  | Denmark | $123.0B | NVO |
| 10 |  | France | $107.3B | SNY |
| 11 |  | Japan | $89.4B | 4519.T |
| 12 |  | United States | $76.1B | REGN |
| 13 |  | Belgium | $54.2B | UCB.VI |
| 14 |  | China | $51.1B | 600276.SS |
| 15 |  | South Korea | $49.2B | 207940.KS |
| 16 |  | United States | $48.8B | ZTS |
| 17 |  | Australia | $47.0B | CSL.AX |
| 18 |  | Germany | $43.5B | BAYN.DE |
| 19 |  | Switzerland | $41.6B | LONN.SW |
| 20 |  | Netherlands | $41.1B | ARGX |